PMID- 34262904
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210716
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 9
DP  - 2021
TI  - Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical 
      Applications.
PG  - 686544
LID - 10.3389/fcell.2021.686544 [doi]
LID - 686544
AB  - Dendritic cells (DCs) are efficient antigen-presenting cells (APCs) and potent 
      activators of naive T cells. Therefore, they act as a connective ring between 
      innate and adaptive immunity. DC subsets are heterogeneous in their ontogeny and 
      functions. They have proven to potentially take up and process tumor-associated 
      antigens (TAAs). In this regard, researchers have developed strategies such as 
      genetically engineered or TAA-pulsed DC vaccines; these manipulated DCs have 
      shown significant outcomes in clinical and preclinical models. Here, we review DC 
      classification and address how DCs are skewed into an immunosuppressive phenotype 
      in cancer patients. Additionally, we present the advancements in DCs as a 
      platform for cancer immunotherapy, emphasizing the technologies used for in vivo 
      targeting of endogenous DCs, ex vivo generated vaccines from peripheral blood 
      monocytes, and induced pluripotent stem cell-derived DCs (iPSC-DCs) to boost 
      antitumoral immunity.
CI  - Copyright (c) 2021 Salah, Wang, Li, Ji, Ou, Qi and Wu.
FAU - Salah, Ahmed
AU  - Salah A
AD  - Department of Biochemistry and Molecular Biology, College of Life Science and 
      Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
FAU - Wang, Hao
AU  - Wang H
AD  - Department of Biochemistry and Molecular Biology, College of Life Science and 
      Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
AD  - Hangzhou Biaomo Biosciences Co., Ltd., Hangzhou, China.
AD  - Asia Stem Cell Therapies Co., Limited, Shanghai, China.
FAU - Li, Yanqin
AU  - Li Y
AD  - Department of Biochemistry and Molecular Biology, College of Life Science and 
      Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
FAU - Ji, Meng
AU  - Ji M
AD  - Hangzhou Biaomo Biosciences Co., Ltd., Hangzhou, China.
FAU - Ou, Wen-Bin
AU  - Ou WB
AD  - Department of Biochemistry and Molecular Biology, College of Life Science and 
      Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
FAU - Qi, Nianmin
AU  - Qi N
AD  - Hangzhou Biaomo Biosciences Co., Ltd., Hangzhou, China.
AD  - Asia Stem Cell Therapies Co., Limited, Shanghai, China.
FAU - Wu, Yuehong
AU  - Wu Y
AD  - Department of Biochemistry and Molecular Biology, College of Life Science and 
      Medicine, Zhejiang Sci-Tech University, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210628
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC8273339
OTO - NOTNLM
OT  - cancer immunotherapy
OT  - cancer vaccines
OT  - dendritic cells
OT  - iPSC-DCs
OT  - induced pluripotent stem cells
COIS- HW and NQ were employed by the company Hangzhou Biaomo Biosciences Co., Ltd., 
      Hangzhou, China and Asia Stem Cell Therapies Co., Limited, Shanghai, China. MJ 
      was employed by the company Hangzhou Biaomo Biosciences Co., Ltd., Hangzhou, 
      China. The remaining authors declare that the research was conducted in the 
      absence of any commercial or financial relationships that could be construed as a 
      potential conflict of interest.
EDAT- 2021/07/16 06:00
MHDA- 2021/07/16 06:01
PMCR- 2021/01/01
CRDT- 2021/07/15 06:23
PHST- 2021/03/27 00:00 [received]
PHST- 2021/05/11 00:00 [accepted]
PHST- 2021/07/15 06:23 [entrez]
PHST- 2021/07/16 06:00 [pubmed]
PHST- 2021/07/16 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcell.2021.686544 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2021 Jun 28;9:686544. doi: 10.3389/fcell.2021.686544. 
      eCollection 2021.